You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


Antibody discovered by RQ Bio enters pivotal research phase

RQ Bio has announced that the first of its discovered monoclonal antibodies to prevent COVID-19 in vulnerable patients – AZD3152 – has entered clinical trials less than 12 months after discovery. It follows AstraZeneca (AZ) receiving a licence for AZD3152 from RQ Bio in May 2022.